Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ebola virus-like particle vaccine + Advax
- Development stage
- Preclinical
- Lead developer
- Vaxine
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Ebola virus-like particle vaccine + Advax is a vaccine candidate developed by Vaxine for the prevention of Ebola virus disease. The vaccine utilizes virus-like particle (VLP) technology to display Ebola virus antigens, mimicking the structure of the virus without being infectious. It is adjuvanted with Advax, Vaxine's proprietary adjuvant based on delta-inulin, which enhances the immune response by activating both the humoral (antibody) and cellular (T-cell) arms of the immune system. This combination is designed to provide robust and long-lasting protection against Ebola virus infection. The project is currently in the preclinical stage of development.
- Other names
- virus-like particle Ebola vaccineebola virus-like particle vaccine + Advax
02
Targets
Zaire ebolavirus glycoproteinTLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on ebola virus-like particle vaccine + Advax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ebola virus-like particle vaccine + Advax.